Mission

Why we exist

300 million people live with rare disease. 95% have no approved treatment. The biology to change that already exists. It is fragmented across literature, clinical data, and experimental systems. Artana assembles it into the holistic causal evidence that FDA basket-trial submissions require.

What we believe

The science exists. The economics don’t.

Gene therapy development costs $500M–$2B. Divided across 200 ultra-rare patients, that’s $2.5–7.5M each. Far above the ~$200K threshold where payers and investors engage. Mechanism-based aggregation is what crosses the threshold.

Different diseases can share the same drug strategy.

Distinct genetic diseases converge on shared biological pathways, protein complexes, and cellular dysfunction. Group patients by mechanism instead of gene and populations aggregate, trials become feasible, and capital can be deployed.

Patients aren’t a marketing line. They’re the data moat.

Direct relationships with rare disease families provide phenotype data and biospecimens that validate cohort analysis. Patient populations no commercial entity can assemble independently.

Cross-species evidence is essential when human data is sparse.

For ultra-rare conditions with ~200 patients, human data alone is insufficient. Mouse, fly, and fish models that recapitulate human disease are how you build the causal chains regulatory submissions require.

The rare disease value chain is forming.

Lean accelerators reduce development cost from $166M to ~$5M. Priority Review Vouchers ($150–205M) provide the exit. The FDA Plausible Mechanism Framework (Feb 2026) makes mechanism-based grouping actionable. Two years ago, none of this existed. Artana is the upstream evidence layer.

We are not a drug company.

We are not a CRO. We are not a database. We are the infrastructure layer that makes mechanism-based medicine actionable.

The team has built this before

Three core team members built rare disease research infrastructure together at the Chan Zuckerberg Initiative across 94 patient organizations. Engineering leadership comes from Stanford Medicine clinical data pipelines: PHI-ready, ontology-clean, production-grade. The patient-founder leadership reflects direct lived experience with the diseases the platform addresses.

Our nonprofit/for-profit structure

Artana Bio is incorporating as a Delaware public benefit corporation. Mission alignment is legally embedded in the company structure. The MED13 Foundation provides patient-community access, IRB-approved biospecimen partnerships, and grant-funded R&D for open-source infrastructure exclusively. Commercial revenue is generated separately through Artana Bio. This is the model proven by CureDuchenne Ventures and the CF Foundation: structural advantage, not cost savings. The nonprofit validates the platform; the for-profit commercializes it.

Next steps

Want context on what Artana does and how we handle clinical data?

Join the waitlist Read the security posture